Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) said the focus will be on executing its five pillars strategy after securing just under £10 million of new investment. So, in the current year, it will aim to drive the utilisation of its groundbreaking MRI lung function technology, grow its user base and broaden reimbursement.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has raised $10 million of new equity with the proceeds earmarked to accelerate the commercialisation of XENOVIEW, the company's MRI technology. The placing, priced at 1p per share, was cornerstoned by major shareholder and industry partners NUKEM and Bracco, which prior to the placing held 10.4% and 7.6% of the company respectively.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has raised $10 million of new equity with the proceeds earmarked to accelerate the commercialisation of XENOVIEW, the company's MRI technology. The placing, priced at 1p per share, was cornerstoned by major shareholder and industry partners NUKEM and Bracco, which prior to the placing held 10.4% and 7.6% of the company respectively.